Eli Lilly is radically changing course after years of inflated prices and come the fourth quarter of this year, making their Humalog and Humulin, their state-of-the-art analog insulins, available for $35/month to those with private health insurance.
We saw this happen earlier this year when Congress passed a bill capping monthly insulin at $35/month for those who have Medicare.
Yet, those who didn’t were left in the dust. Now Eli Lilly CEO David Ricks says, “We are doing this completely voluntarily because it’s time and it’s the right thing to do.” Well, we might argue the same was true years ago, but that said, this really is a big loosening of the stranglehold Eli Lilly has had on the pricing of insulin, a drug as you well know, millions of people will die without access to.
One can only hope the two other giant Pharma insulin manufacturers — Sanofi and Novo Nordisk — follow suit.
For the full article, click here.
One thought on “Cost of a vial of Humalog will drop from $274.70 to $66.40 end of year”
Pingback: Novo Nordisk follows Eli Lilly to lower insulin prices next year | Diabetes Stories